AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis

Table 2 Characteristics of studies included in the meta-analysis

First author	Year	Country	Ethnicity	Case/control	Control select	Cancer	Genotyping method	HWE	Quality scores
Kanzaki H	2006	Japan	Asian	160/110	PB	LC	PCR-RFLP	0.863	12
Kanzaki H	2006	Japan	Asian	113/110	PB	CC	PCR-RFLP	0.863	12
Kanzaki H	2006	Japan	Asian	63/110	PB	H & NC	PCR-RFLP	0.863	11
Gunes EG	2009	Turkey	Caucasian	100/100	HB	LC	PCR-RFLP	0.500	10
Gunes EG	2010	Turkey	Caucasian	100/100	HB	AS	PCR-RFLP	0.500	10
E Pinarbasi	2010	Turkey	Caucasian	84/100	HB	PC	PCR-RFLP	0.882	9
Mostowska A	2014	Polish	Caucasian	282/282	HB	OC	HybProbe	0.546	11
Liu X	2014	China	Asian	56/50	HB	PTC	MALDI-TOF-MS	0.019	6
Liu D	2014	China	Asian	520/555	PB	LC	TaqMan	0.457	14
Ma C	2014	China	Asian	103/100	HB	PC	SNaPshot	0.153	10

PB Population–based, HB Hospital–based, LC lung cancer, CC colorectal cancer, H&NC head and neck cancer, As astrocytoma, PC prostate cancer, OC Ovarian cancer, PTC papillary thyroid carcinoma, PCR-RFLP Polymerase chain reaction-restriction fragment length polymorphism, HWE Hardy–Weinberg equilibrium in control population

ISSN: 1475-2867